The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

MAKING A DIFFERENCE

CHARITY PARTNERS

KEEP UP TO DATE

ON ALL THE LATEST PRODUCTS

Enter your email address:

TESTIMONIALS

Thank you again for all of your help throughout the process of purchasing the US Osteoarthritis Market Highlight - 2014 report.
I appreciate your promptness in responding to my emails and your sense of urgency.Frederique F BuntoumGlobal Marketing Business AnalystBioventus LLC